Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
Breast Cancer
DRUG: TAS-108
To evaluate the safety of TAS-108 administered on this schedule, Treatment-emergent adverse events, serious adverse events, bone mineral density, Up to 4 years and 3 months|To investigate the comparative concentrations of TAS-108 and its metabolites in tumor tissue and blood at steady-state, Up to 4 years and 3 months|To determine the time to progression of TAS-108 administered on this schedule, Up to 4 years and 3 months
The objective of this study is to investigate the efficacy and safety of TAS-108 administered in postmenopausal patients with locally advanced or locally recurrent inoperable or progressive metastatic breast carcinoma who have previously responded to one or two standard endocrine therapies, with or without one prior chemotherapy.